Erbitux® (cetuximab) is an IgG1 monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR). Erbitux® is approved for:

  • Epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
  • Squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease and in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

  • Product Information – European Medicines Agency